You are here:  Home » Research Funding » Offices & Programs » Office of Translational Research » 

Skip secondary menu

Office of Translational Research

The mission of the NINDS Office of Translational Research (OTR) is to facilitate the preclinical discovery and development of new therapeutic interventions for neurological disorders.

NIH Webinar on New Programs to Accelerate Drug Discovery
A collaboration of the University-Industry Demonstration Partnership
(UIDP)
and the National Institutes of Health
Tuesday, March 27, 2012, 1:00 pm to 2:30 pm ET
For more information and to register: http://center.ncet2.org/index.php?option=com_content&view=article&id=437.


Therapeutic Development Programs


 
View mode:

  • Target
    ID
  • Assay Development
  • Screen for
    Hit
  • Hit to
    Lead
  • Proof of Principle
  • Lead Optimization
  • Preclinical Safety/Tox
  • First in Human

  • Anticonvulsant Screening Program (ASP)

    • Provides services to characterize, optimize, and profile novel antiseizure/anticonvulsant agents by using a battery of disease-specific and mechanistic models of epilepsy (NINDS)

  • Exploratory/Developmental Projects in Translational Research

    • Provides funding (R21) for preclinical development tasks, including creation and validation of screening assays, development of animal models for therapy development, identification of candidate therapeutics, and development of preliminary animal efficacy data (NINDS)

  • Cooperative Program

    • Provides cooperative agreement funding (U01, U54, U24) for the preclinical development and testing of novel therapeutics and devices, in preparation for an IND/IDE (NINDS)

  • Translational SBIR

    • Provides cooperative agreement funding (U44) to small businesses for the preclinical development and testing of novel therapeutics and devices, in preparation for an IND/IDE. (NINDS)

  • Small Business Program: SBIR & STTR

    • Provides funding (R41, R42, R43, R44, U44) to small businesses to engage in research and development with the potential for commercialization (NINDS)

  • Spinal Muscular Atrophy (SMA) Project

    • A "virtual pharma" network of contracts for industry-style drug development aimed at developing a safe and effective drug for spinal muscular atrophy (SMA) (NINDS)

  • Blueprint Neurotherapeutics Network

    • Provides cooperative agreement funding (U01) and free access to millions of dollars-worth of contracted drug development services and expertise to transform small molecule probe compounds into drug candidates for diseases and disorders of the nervous system (Trans-NIH)

  • Assay
    Development

    • Provides funding (R21) to develop and characterize assays that can be used to identify small molecule interactions via high-throughput screening of small molecular compound libraries and to chemically optimize active compounds as molecular probes (Trans-NIH)

  • Molecular
    Libraries

    • Provides funding (R03) and access to high-throughput screening services in the Molecular Libraries Probe Production Centers Network (Trans-NIH)

  • Small Molecule
    Optimization

    • Provides funding (R21) for medicinal chemistry to optimize small molecule probes for investigating biological function in the nervous system (Trans-NIH)

  • Drug Discovery
    R01s

    • Provides funding (R01) for the implementation of novel molecular probes in target validation studies and proof-of-principle preclinical studies confirming the link of a target, mechanism, or phenotype with neurological disease onset or progression (Trans-NIH)

  • NIH-RAID

    • NIH-Rapid Access to Interventional Development (RAID) provides services for preclinical testing and manufacturing of therapeutic candidates (Trans-NIH)

  • Countermeasures Against Chemical Threats (CounterACT)

    • Provides funding (U01, U54, R21, U44, contracts) and research services to develop products to prevent, diagnose, and treat the conditions caused by exposure to toxic chemicals (Trans-NIH)

Legend

  •  NINDS
  •  Trans-NIH


Workshop Summary


Office of Translational Research Funding Initiatives


Office of Translational Research Program Staff


Scientific Staff Research Area
Rajesh Ranganathan, Ph.D.
Associate Director

  
Rebecca Farkas, Ph.D.
Program Director

 Blueprint Neurotherapeutics Network, Medicinal Chemistry, Roadmap Molecular Libraries
Jill Heemskerk, Ph.D.
Program Director

 Spinal Muscular Atrophy Project, Blueprint Neurotherapeutics Network
David Jett, Ph.D.
Program Director

 Counterterrorism (CounterACT) Programs, Neurotoxicology, Roadmap Molecular Libraries
Yuan Liu, Ph.D.
Program Director
Chief, Office of International Activities

 Neuroinformatics, Computational Neuroscience, International Activities
Stacey Chambers
Program Analyst

 CounterACT
Tracy Chen, Ph.D., D.A.B.T.
Scientific Research Specialist

 Anticonvulsant Screening Program (ASP)
Charles Cywin, Ph.D.
Project Manager

 Blueprint Neurotherapeutics Network

Stephanie Fertig, MBA
Research Project Manager

Small business (SBIR, STTR)
Jeff Jiang, Ph.D.
Scientific Research Specialist

 Anticonvulsant Screening Program (ASP)
Jenna Linde
Program Analyst

 Blueprint Neurotherapeutics Network
Linda McGavern, Ph.D.
Project Manager

 NINDS Cooperative Program in Translational Research
Taek Oh
Information Technology Specialist

 Anticonvulsant Screening Program (ASP)

Christina Vert, M.S.
Health Program Specialist

Small business (SBIR, STTR) and NINDS Cooperative Program in Translational Research

David Yeung, Ph.D.
Program Specialist/Project Manager

Counterterrorism (CounterACT) Programs

Eric Nelson, Ph.D.
Consultant

Blueprint Neurotherapeutics Network

 

Address

NINDS Office of Translational Research Neuroscience Center
6001 Executive Blvd
Bethesda, Maryland 20892
For courier service only, use Rockville, Maryland 20852
Phone: (301) 496-1779